Venetoclax-Obinutuzumab Yields Comparable Efficacy in Fit and Unfit Patients With CLL - Oncology Nurse Advisor Researchers assessed whether venetoclax-obinutuzumab would be safe and effective in fit and unfit patients with previously untreated CLL.

Venetoclax–obinutuzumab demonstrated comparable efficacy and tolerability in both fit and unfit patients with previously untreated chronic #lymphocyticLeukemia. Published in @bloodjournals.hematology.org and @hematologyadvisor.bsky.social.

https://bit.ly/4cvVQvQ

#lymsm #leusm #CLL

Venetoclax-Obinutuzumab Yields Comparable Efficacy in Fit and Unfit Patients With CLL Researchers determined venetoclax-obinutuzumab demonstrated comparable efficacy and tolerability in both fit and unfit patients with previously untreated CLL.

Venetoclax–obinutuzumab demonstrated comparable efficacy and tolerability in both fit and unfit patients with previously untreated chronic #lymphocyticLeukemia. Published in @bloodjournal.bsky.social.

https://bit.ly/3N3LYyQ

#CLL #leusm

Frailty Scale May Predict Treatment Cessation in Older Patients With CLL - Oncology Nurse Advisor After adjustment for other factors, a CFS of 3 or higher and relapsed/refractory disease were the only independent predictors of early zanubrutinib discontinuation.

The Clinical Frailty Scale was associated with early treatment discontinuation among older adults with chronic #lymphocyticLeukemia treated with zanubrutinib. Published in @rarediseaseadvisor.bsky.social.

https://bit.ly/4q7Shix

#CLL #leusm

Live Cell Phenotyping Stratifies CLL and Predicts Response to Targeted Therapy Machine-learning analysis of untreated CLL samples identified 5 stable patient clusters associated with distinct therapeutic sensitivities.

Live cell imaging-derived phenotypes reliably forecasted clinically relevant heterogeneity in chronic #lymphocyticLeukemia and delineated patient cohorts likely to respond to ruxolitinib, venetoclax, or their combination. Published in @cp-iscience.bsky.social.

https://bit.ly/3Z0pbq4

#CLL #leusm

Prognosis Worsens Once Patients Exhaust BTKi and BCL2i in CLL Longitudinal data reveal consistent initial responsiveness to targeted agents but limited durability once patients cycle through both BTKi and BCL2i classes.

Patients with chronic #lymphocyticLeukemia who discontinued covalent BTKi and later required BCL2i therapy faced diminishing clinical benefit, underscoring a pressing therapeutic gap. From @rarediseaseadvisor.bsky.social.

https://bit.ly/3MX8zg6

#CLL #leusm

ASH 2025: Refining the Modern Management of CLL in the Era of Targeted Therapies Significant treatment options are changing the management of CLL, according to research presented at the ASH Annual Meeting 2025.

Significant treatment options with targeted therapies are changing the management of chronic #lymphocyticLeukemia. Presented at #ASH25 with Adam Kittai, MD of Icahn Mount Sinai.

https://bit.ly/44GOoZZ

#CLL #leusm

Granulomatous Acute Interstitial Nephritis Can Cause Renal Dysfunction in CLL The patient initiated treatment with zanubrutinib and high-dose corticosteroids, resulting in partial improvement in renal function.

Granulomatous acute interstitial nephritis is a rare but important cause of renal dysfunction in patients with chronic #lymphocyticLeukemia. From @rarediseaseadvisor.bsky.social.

https://bit.ly/49u4fym

#CLL #leusm

Secondary Malignancies in CLL Highlight the Need for Vigilant Surveillance CLL-related immune dysfunction, along with therapy-associated immunosuppression, contributes to impaired tumor surveillance.

Patients with chronic #lymphocyticLeukemia are at increased risk for secondary malignancies, which often have aggressive courses and poor outcomes. Published in @cureusmedical.bsky.social and @rarediseaseadvisor.bsky.social.

https://bit.ly/4gjUJPC

#leusm #CLL

Machine Learning Models May Improve CLL Diagnosis and Management Researchers determined machine learning models developed to support the management of CLL have demonstrated positive outcomes.

A review of #machinelearning models developed to support the management of chronic #lymphocyticLeukemia have demonstrated positive outcomes, including accurate diagnosis and improved work flow.

https://bit.ly/3HQxIqV

#lymsm #leusm

Tomorrow's #ASCO25 Education Session on "When and How Long to Treat Chronic #LymphocyticLeukemia" has an accompanying #ASCOEdBook paper. Take a look: ascopubs.org/doi/10.1200/...
#lymsm

Pharmacist-Led Clinic for Administering Venetoclax Safe, Effective for CLL - Oncology Nurse Advisor Researchers sought to determine whether a pharmacist-led clinic for administering venetoclax would be effective for patients with CLL.

Use of a pharmacist-led clinic for administering venetoclax was considered safe and effective in a study including patients with chronic #lymphocyticLeukemia that was led by a research team based in Edmonton, Alberta, Canada.

bit.ly/4k5NxHt

#CLL

Fatty Acid Oxidation Inhibition Enhanced PI3K Inhibitor Efficacy in CLL A 3-gene fatty acid metabolism score (LPL, SOCS3, CNR1) predicted prognosis in CLL and correlated with immune phenotypes.

A prognostic risk score based on fatty acid metabolism gene expression revealed distinct immune phenotypic differences and implicated fatty acid oxidation in chronic #lymphocyticLeukemia progression. Published in @rarediseaseadvisor.bsky.social.

bit.ly/3GE6Qt4

#CLL